# **BCCA Protocol Summary for Palliative Therapy for Advanced Breast Cancer Using Exemestane**

Protocol Code:

**Tumour Group:** 

**Contact Physician:** 

**ELIGIBILITY**:

- hormonal treatment for hormone receptor positive advanced breast cancer in postmenopausal women
- consideration should first be given to using BRAVEVEX for fit patients after recurrence or progression on a non-sterioidal aromatase inhibitor (anastrozole or letrozole).

## **EXCLUSION CRITERIA:**

Premenopausal women.

## TESTS:

None required.

### TREATMENT:

Exemestane 25 mg po daily until evidence of progression.

### Contact Dr. Susan Ellard or tumour group delegate at (250) 712-3900 or 1-888-563-7773 with any problems or questions regarding this treatment program.

Date Activated: 01 July 2001

Date Revised: 01 May 2014 (Minor typo corrected)

### **REFERENCES**:

- 1. Kaufmann M, Bajetta E, Dirix LY et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 2000;18:1399-411.
- 2. Lonning PE, Bajetta E, Murray R et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000;18:2234-44.

BC Cancer Agency Protocol Summary BRAVEXE

Page 1 of 1 Warning: The information contained in these documents are a statement of consensus of BC Cancer Agency professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is a subject to BC Cancer Agency's terms of use available at www.bccancer.bc.ca/legal.htm

BRAVEXE Breast Dr. Susan Ellard